Europe Advanced Wound Care Market By Type (Dressings, Active Wound Care, Therapy Devices), By Application (Surgical Wounds, Ulcer), By End-User (In-Patient Facility, and Out-Patient Facility), and By Countries - Analysis & Forecast to 2021

The Europe advanced wound care market was valued at USD 1,964.7 million in 2015, which is projected to reach USD 2,893.3 million by 2021, at a CAGR of 6.7% during the forecast period. The major players in this market include Smith & Nephew Plc (U.K.), Mölnlycke Health Care (Sweden), ConvaTec, Inc. (U.S.), Laboratoires URGO (France), Coloplast Group (Denmark), Medline Industries, Inc. (U.S.), Organogenesis, Inc. (U.S.), Shire (Ireland), MiMedx Group, Inc. (U.S.), and Integra Life Sciences Corporation (U.S.). Smith & Nephew Plc and ConvaTec, Inc. dominated the market and contributed shares of 26.0% and 15.7%, respectively, in 2015.

Inquiry before Buying:
http://www.micromarketmonitor.com/contact/5474529395-inquery_before_buy.html

Smith & Nephew Plc, a London based company, accounted for a significant share of 26.0% of the Europe advanced wound care market in 2015. In July 2014, the company launched PICO, a pocket-sized, single use Negative Pressure Wound Therapy (NPWT) system for the treatment of acute and chronic wounds in Japan. This new product launch helped the company in strengthening its customer base as well as product portfolio. Earlier, in December 2013, it had launched DURAFIBER Ag, a highly absorbent fiber dressing, in the global market. Prior to this launch in the global market, the product was available only in the U.S. market. This launch helped the company strengthen its wound management product portfolio.

Request for Customizations:
http://www.micromarketmonitor.com/contact/5474529395-request_for_customization.html

In 2015, ConvaTec, Inc., a leading global medical products and technologies company, accounted for a share of 15.7% of the Europe Advanced Wound care market. In May 2015, ConvaTec announced the availability of its AQUACEL® Foam Dressing into a range of new rectangular sizes designed for various anatomical wound care applications. This product portfolio expansion will enable the company to satisfy the needs of customers, and in turn strengthening its customer base. Earlier, in February 2014, the company launched AQUACEL Ag+, a wound dressing that kills infectious pathogens by penetrating through the wound biofilm. This product was launched in European and Asia-Pacific countries. It helped the company increase its existing product portfolio.